Shoulder Innovations Raises 2026 Revenue Outlook After 56% Q2 Surge
SI has more than doubled off its 52-week low of $10.92 on light trading volume (0.4× avg).
Summary
Q2 revenue hit $17.2M, up 56% YoY, driven by 50% implant volume growth and higher ASPs. Gross margin expanded to 78.3%. Full-year guidance raised to $67M-$69M, implying ~44% growth at midpoint. Operating loss widened to $10M on heavy R&D and commercial investment, but cash remains strong at $99M after recent $50M credit facility. The raised outlook and new product launches (N-22 glenosphere, TPS baseplate) signal accelerating commercial traction. This follows Q1's 65% revenue jump and the June debt refinancing, reinforcing a growth investment cycle. Watch for sustained margin improvement and cash burn trajectory in H2.
At the time of this announcement, SI was trading at $22.43 on NYSE in the Life Sciences sector, with a market capitalization of approximately $465.2M. The 52-week trading range was $10.92 to $24.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.